BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26628333)

  • 1. A novel injectable phospholipid gel co-loaded with doxorubicin and bromotetrandrine for resistant breast cancer treatment by intratumoral injection.
    Luo JW; Zhang T; Zhang Q; Cao X; Zeng X; Fu Y; Zhang ZR; Gong T
    Colloids Surf B Biointerfaces; 2016 Apr; 140():538-547. PubMed ID: 26628333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
    Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
    Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel doxorubicin-loaded in situ forming gel based high concentration of phospholipid for intratumoral drug delivery.
    Wu W; Chen H; Shan F; Zhou J; Sun X; Zhang L; Gong T
    Mol Pharm; 2014 Oct; 11(10):3378-85. PubMed ID: 24735404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
    Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-Assembled Indomethacin Dimer Nanoparticles Loaded with Doxorubicin for Combination Therapy in Resistant Breast Cancer.
    Wang X; Cheng X; He L; Zeng X; Zheng Y; Tang R
    ACS Appl Mater Interfaces; 2019 Aug; 11(32):28597-28609. PubMed ID: 31314480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot.
    Kim DY; Kwon DY; Kwon JS; Park JH; Park SH; Oh HJ; Kim JH; Min BH; Park K; Kim MS
    Biomaterials; 2016 Apr; 85():232-45. PubMed ID: 26874285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of an intratumorally injected in situ-forming doxorubicin/poly(ethylene glycol)-b-polycaprolactone diblock copolymer.
    Kang YM; Kim GH; Kim JI; Kim DY; Lee BN; Yoon SM; Kim JH; Kim MS
    Biomaterials; 2011 Jul; 32(20):4556-64. PubMed ID: 21440935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
    Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
    Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan-alginate BSA-gel-capsules for local chemotherapy against drug-resistant breast cancer.
    Shen H; Li F; Wang D; Yang Z; Yao C; Ye Y; Wang X
    Drug Des Devel Ther; 2018; 12():921-934. PubMed ID: 29719378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
    Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
    Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
    Sheng Y; You Y; Chen Y
    Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
    Cui T; Zhang S; Sun H
    Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
    Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
    Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
    Xu HB; Shen ZL; Fu J; Xu LZ
    Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.